Novel small molecule activators enhance NRF2-dependent gene expression for therapeutic applications, targeting deregulated signaling.
Embodiments are directed to a series of novel small molecule activators of NRF2 dependent gene expression that are evaluated in an effort to develop therapeutic methods against diseases with deregulated KEAP1-NRF2 signaling.
No takes yet. Share an insight, caveat, or question.
Moellering et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: